| __timestamp | Merus N.V. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 10811000 |
| Thursday, January 1, 2015 | 839656 | 33001000 |
| Friday, January 1, 2016 | 4478145 | 64936000 |
| Sunday, January 1, 2017 | 16432324 | 99909000 |
| Monday, January 1, 2018 | 11890871 | 127724000 |
| Tuesday, January 1, 2019 | 34110000 | 161524000 |
| Wednesday, January 1, 2020 | 35781000 | 182933000 |
| Friday, January 1, 2021 | 40896000 | 219982000 |
| Saturday, January 1, 2022 | 52200000 | 278139000 |
| Sunday, January 1, 2023 | 59836000 | 309799000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart highlights the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Merus N.V. over the past decade. Since 2014, Ultragenyx has consistently outpaced Merus in SG&A spending, reflecting its aggressive growth strategy. By 2023, Ultragenyx's expenses soared to nearly 310% of its 2014 levels, reaching approximately $310 million. In contrast, Merus, with a more conservative approach, saw its SG&A costs increase by about 1,450% over the same period, peaking at nearly $60 million. This divergence underscores the different paths these companies have taken in scaling their operations. As investors and industry watchers analyze these trends, the question remains: will Ultragenyx's high expenditure translate into greater market dominance, or will Merus's leaner model prove more sustainable in the long run?
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Merus N.V.
GSK plc and Merus N.V.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Perrigo Company plc Trends and Insights
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Merus N.V. vs Ligand Pharmaceuticals Incorporated